Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

HWK-016

Antibody-drug conjugate · Cytotoxic, directed at MUC16 (mucin-16, CA-125) (MUC16) · developed by Whitehawk Therapeutics

Phase 1 Most advanced trial
WHWK Developer
1 Registered trials

What is HWK-016?

HWK-016 is an antibody-drug conjugate that targets MUC16 (mucin-16). It is being studied in platinum-resistant ovarian cancer and endometrial cancer.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Antibody-drug conjugate
Targets
MUC16 (mucin-16, CA-125) (MUC16)
Mechanism
Cytotoxic, directed at MUC16 (mucin-16, CA-125) (MUC16)
Therapy area
Oncology
Developer
Whitehawk Therapeutics, Inc. (WHWK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07470853 Phase 1 PROC Recruiting WHWK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Endometrial CancerPlatinum Resistant Ovarian CancerPROC

Other drugs acting on MUC16

More from Whitehawk Therapeutics

Sources

Updated Nov 1, 2026. Something wrong or missing? Report it on the WHWK page.

Follow WHWK, the company behind HWK-016

See WHWK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

WHWK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.